THURSDAY, April 22 (HealthDay News) -- After two years of follow-up, a new-generation sirolimus- and probucol-eluting stent (Dual-DES) maintains an advantage over sirolimus-eluting stents (SES) and zotarolimus-eluting stents (ZES), though the safety profiles of the three types are similar, according to research published online April 21 in the Journal of the American College of Cardiology.
Robert A. Byrne, of the Technische Universität in Munich, Germany, and colleagues followed 1,007 patients undergoing coronary artery stenting of de novo lesions in native vessels for two years. The patients were randomized to one of three types of stent: SES, Dual-DES, or ZES. Patients underwent follow-up angiography at six, eight, and 24 months after stenting.
The researchers found that there were no significant differences between the groups regarding rates of myocardial infarction or death (P = 0.61) or definite stent thrombosis (P = 0.87). The two-year target lesion revascularization (TLR) was 10.7 percent for SES, 7.7 percent for Dual-DES, and 14.3 percent for ZES (P = 0.009). Incident TLR for the Dual-DES group (0.9 percent) during the second year of follow-up was significantly lower than in the SES group (3.6 percent; P = 0.009) but comparable with the ZES group (0.7 percent; P = 0.72).
"The results of the ISAR-TEST-2 trial revealed no evidence of a differential safety profile between the Cypher SES, a novel polymer-free sirolimus- and probucol-eluting Dual-DES, and the Endeavor ZES out to two years. Furthermore, the antirestenotic efficacy of both the Dual-DES and the ZES remained durable between one and two years, with Dual-DES maintaining an advantage over the entire two-year period," the authors write.
Two of the authors have submitted a patent application for the Dual-DES coating, and three authors have received lecture fees from Cordis and/or Medtronic, which make the SES and ZES, respectively.
Abstract
Full Text (subscription or payment may be required)
